Literature DB >> 21885392

The prognostic impact of follow-up assessments in patients with idiopathic pulmonary arterial hypertension.

N Nickel1, H Golpon, M Greer, L Knudsen, K Olsson, V Westerkamp, T Welte, M M Hoeper.   

Abstract

Current guidelines for the treatment of patients with idiopathic pulmonary arterial hypertension (IPAH) recommend basing therapeutic decision-making on haemodynamic, functional and biochemical variables. Most of these parameters have been evaluated as risk predictors at the time of diagnosis. The aim of the present study was to assess the prognostic impact of changes in these parameters after initiation of targeted therapy. A cohort of 109 patients with IPAH who had undergone haemodynamic, functional and biochemical assessments at baseline and 3-12 months after initiation of pulmonary arterial hypertension (PAH)-targeted therapy, were followed for a median 38 months in order to determine predictors of mortality at baseline and during the course of their disease. Within the observation period, 53 (48.6%) patients died and four (3.7%) underwent lung transplantation. Kaplan-Meier estimates for transplantation-free survival were 92%, 67%, and 51% at 1, 3, and 5 yrs, respectively. Among baseline variables, 6-min walk distance, right atrial pressure, cardiac index, mixed-venous oxygen saturation (S(v,O(2))) and N-terminal-pro brain natriuretic peptide (NT-proBNP) were independent predictors of survival. During follow-up, changes in World Health Organization functional class, cardiac index, S(v,O(2)) and NT-proBNP proved significant predictors of outcome. When assigned to prognostic groups, improvements as well as deteriorations in these parameters after initiation of PAH-targeted therapy had a strong impact on survival. Measurements obtained at follow-up had a higher predictive value than variables obtained at baseline. Changes in established predictors of outcome during the course of the disease provide important prognostic information in patients with IPAH.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21885392     DOI: 10.1183/09031936.00092311

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  77 in total

1.  Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model.

Authors:  Marius M Hoeper; Tilmann Kramer; Zixuan Pan; Christina A Eichstaedt; Jens Spiesshoefer; Nicola Benjamin; Karen M Olsson; Katrin Meyer; Carmine Dario Vizza; Anton Vonk-Noordegraaf; Oliver Distler; Christian Opitz; J Simon R Gibbs; Marion Delcroix; H Ardeschir Ghofrani; Doerte Huscher; David Pittrow; Stephan Rosenkranz; Ekkehard Grünig
Journal:  Eur Respir J       Date:  2017-08-03       Impact factor: 16.671

2.  Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension.

Authors:  Athénaïs Boucly; Jason Weatherald; Laurent Savale; Xavier Jaïs; Vincent Cottin; Grégoire Prevot; François Picard; Pascal de Groote; Mitja Jevnikar; Emmanuel Bergot; Ari Chaouat; Céline Chabanne; Arnaud Bourdin; Florence Parent; David Montani; Gérald Simonneau; Marc Humbert; Olivier Sitbon
Journal:  Eur Respir J       Date:  2017-08-03       Impact factor: 16.671

Review 3.  Treatment of pulmonary arterial hypertension in children.

Authors:  Heiner Latus; Tammo Delhaas; Dietmar Schranz; Christian Apitz
Journal:  Nat Rev Cardiol       Date:  2015-02-03       Impact factor: 32.419

4.  Long-Term Survival of Patients with Pulmonary Arterial Hypertension at a Single Center in Taiwan.

Authors:  Le-Yung Wang; Kuang-Tso Lee; Chia-Pin Lin; Lung-An Hsu; Chun-Li Wang; Tsu-Shiu Hsu; Wan-Jing Ho
Journal:  Acta Cardiol Sin       Date:  2017-09       Impact factor: 2.672

Review 5.  Medical Therapies for the Treatment of Pulmonary Arterial Hypertension: How Do We Choose?

Authors:  Alison M MacKenzie; Andrew J Peacock
Journal:  Curr Hypertens Rep       Date:  2015-07       Impact factor: 5.369

Review 6.  Biomarkers and prognostic indicators in pulmonary arterial hypertension.

Authors:  Carlos Jardim; Rogerio Souza
Journal:  Curr Hypertens Rep       Date:  2015-06       Impact factor: 5.369

7.  Key topics in pulmonary vascular diseases (assembly 13) from the European Respiratory Society 2018 Parisian Congress.

Authors:  Sheila Ramjug; Anton Vonk Noordegraaf; Marion Delcroix
Journal:  J Thorac Dis       Date:  2018-09       Impact factor: 2.895

8.  Is it possible to apply the treat-to-target strategy in primary Sjögren's syndrome-associated pulmonary arterial hypertension?

Authors:  Ziwei Liu; Jieying Wang; Jinzhi Lai; Qian Wang; Jiuliang Zhao; Can Huang; Xiaoxi Yang; Junyan Qian; Hui Wang; Xiaoxiao Guo; Yongtai Liu; Zhuang Tian; Mengtao Li; Yan Zhao; Xiaofeng Zeng
Journal:  Clin Rheumatol       Date:  2018-07-24       Impact factor: 2.980

9.  Plasma MMP2/TIMP4 Ratio at Follow-up Assessment Predicts Disease Progression of Idiopathic Pulmonary Arterial Hypertension.

Authors:  Veronika Wetzl; Svenja Lena Tiede; Lothar Faerber; Norbert Weissmann; Ralph Theo Schermuly; Hossein Ardeschir Ghofrani; Henning Gall
Journal:  Lung       Date:  2017-05-17       Impact factor: 2.584

10.  Noninvasive model including right ventricular speckle tracking for the evaluation of pulmonary hypertension.

Authors:  Yossra Mahran; Robert Schueler; Marcel Weber; Carmen Pizarro; Georg Nickenig; Dirk Skowasch; Christoph Hammerstingl
Journal:  World J Cardiol       Date:  2016-08-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.